Manufacturing

Articles

The results found that repeatability testing found all 15 processes to be with in specification for target final concentration.

Real-Time Process Management System Reliable to Reach Target Final Concentration 

Monil Malhotra, vice-president of Industrial Software at Emerson, discusses the  growing demand for software solutions in the pharma industry.

Examining Software as a Solution with Monil Malhotra (Emerson Automation Exchange)

Claudio Fayad, VP of Technology, Process Systems, and Solutions discusses the intersection of automation and data security in the pharma industry.

Addressing Data Security with Claudio Fayad (Emerson Automation Exchange)

Nathan Pettus, president of Process Systems and Solutions at Emerson, discusses how automation is impacting recent sustainability technologies and solutions.

Exploring Automation and Sustainability with Nathan Pettus (Emerson Automation Exchange)

Interviews hosted on-site at the Emerson Automation Exchange in Grapevine, Texas, from October 24th to October 28th, 2022.

Emerson Automation Exchange Highlights

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As new manufacturing processes and technologies are introduced to meet demand and overcome challenges, understanding also needs to improve to ensure the right balance is achieved.  

Balancing Change and Certainty in Manufacturing 

Organizations can better understand the maturity of AI-driven automation technology across their organization’s IT landscape through effective pharmacovigilance.

Pharmacovigilance Automation

Jennifer Markarian is a contributing editor for 

PAT is crucial to process control and real-time release in continuous manufacturing of solid-dosage drugs. 

Implementing Process Analytical Technology

Shifts in pharmaceutical packaging have spurred tremendous growth in the pre-filled syringe fill/finish industry. 

Automated Inspection of Pre-filled Syringes and Biologics During Fill/Finish

Mark Eller, PhD, is senior vice-president (SVP) of Research and Development at Aria Pharmaceuticals. Eller has held several vice-president/SVP roles leading teams from discovery through approval at large and mid-sized pharma companies, including Jazz, Quintiles (now IQVIA), and HMR (now Sanofi). Eller is co-inventor on 30 patents and has led health authority presentations and negotiations, including six FDA advisory committee meetings. He has co-authored numerous scientific publications and served as an adjunct professor of Pharmaceutics at the University of Cincinnati. Eller received his Pharmacy degree and PhD in Pharmaceutics from the University of Iowa.

Advancing the use of AI to understand the whole of a disease can reveal drug development insights that lead to drug discovery breakthroughs.

Process Control, Automation, and PAT